Alignment Healthcare (NASDAQ:ALHC) Reaches New 52-Week Low - What's Next?

Key Points

• Alignment Healthcare shares plunged 19.9%, reaching a new 52-week low of $9.94 before recovering slightly to $10.37. The selloff followed concerns about Medicare Advantage star ratings, reimbursement, enrollment and profitability.
• Investor sentiment was further pressured by two law-firm investigations into potential securities-law violations and recent insider selling, including approximately $7.1 million in sales by company insiders.
• Despite the decline, analysts maintain a “Moderate Buy” consensus with an average price target of $23.60, while the company recently exceeded quarterly earnings and revenue expectations, reporting $1.34 billion in revenue, up 31.6% year over year.

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $9.94 and last traded at $10.37, with a volume of 28545880 shares trading hands. The stock had previously closed at $12.94.

More Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Neutral Sentiment: Unusual options activity provided a potentially bullish—but highly speculative—signal: investors purchased 19,456 ALHC call options, roughly 996% above the average daily volume of 1,775 contracts. Options activity alone does not confirm a change in the company’s outlook.
• Negative Sentiment: Reports from the Baird conference said Alignment’s shares fell after comments concerning Medicare Advantage star ratings. The lack of clear reassurance or detail appears to have increased concerns about the company’s future reimbursement, enrollment and profitability prospects. Alignment falls after comments at Baird investor conference
• Negative Sentiment: Rosen Law Firm announced an investigation into potential securities claims, alleging that Alignment may have issued materially misleading business information. While the announcement does not establish wrongdoing, it adds litigation and reputational risk. Rosen Law Firm investigation
• Negative Sentiment: Kaplan Fox separately reported an investigation into potential securities-law violations, reinforcing investor concerns following the conference disclosures. Kaplan Fox investigation
• Negative Sentiment: A recent SEC filing showed an Alignment insider sold approximately $7.1 million of stock, including a reported $4.9 million sale by the CEO. Insider selling is not necessarily evidence of trouble, but the transactions may further weigh on sentiment. Alignment Healthcare insider stock sale

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. KeyCorp reiterated an "overweight" rating on shares of Alignment Healthcare in a report on Wednesday, June 10th. JPMorgan Chase & Co. lowered their target price on shares of Alignment Healthcare from $26.00 to $22.00 and set an "overweight" rating for the company in a report on Tuesday, August 4th. Wall Street Zen lowered shares of Alignment Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. UBS Group reaffirmed a "neutral" rating on shares of Alignment Healthcare in a research note on Wednesday, July 8th. Finally, Zacks Research cut shares of Alignment Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Alignment Healthcare currently has a consensus rating of "Moderate Buy" and an average target price of $23.60.

Alignment Healthcare Stock Down 19.9%

The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 54.58 and a beta of 1.11. The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 1.22. The firm has a 50 day moving average price of $15.66 and a two-hundred day moving average price of $17.90.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.04. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. The firm had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the company earned $0.07 EPS. The company's revenue was up 31.6% on a year-over-year basis. On average, equities analysts expect that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current fiscal year.

Insider Transactions at Alignment Healthcare

In other news, President Dawn Maroney sold 122,707 shares of the firm's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $12.68, for a total value of $1,555,924.76. Following the transaction, the president owned 794,606 shares of the company's stock, valued at approximately $10,075,604.08. This trade represents a 13.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Joseph Konowiecki sold 25,000 shares of Alignment Healthcare stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $24.00, for a total transaction of $600,000.00. Following the transaction, the executive vice president owned 1,103,816 shares in the company, valued at $26,491,584. The trade was a 2.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,326,577 shares of company stock valued at $19,907,564 over the last 90 days. Corporate insiders own 5.20% of the company's stock.

Institutional Investors Weigh In On Alignment Healthcare

Large investors have recently modified their holdings of the stock. Allworth Financial LP grew its stake in Alignment Healthcare by 8.9% during the 4th quarter. Allworth Financial LP now owns 6,917 shares of the company's stock valued at $137,000 after acquiring an additional 566 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Alignment Healthcare by 9.2% during the first quarter. PNC Financial Services Group Inc. now owns 11,445 shares of the company's stock worth $202,000 after purchasing an additional 962 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Alignment Healthcare by 46.6% during the second quarter. GAMMA Investing LLC now owns 3,368 shares of the company's stock worth $80,000 after purchasing an additional 1,070 shares during the period. Versant Capital Management Inc grew its position in Alignment Healthcare by 463.3% during the second quarter. Versant Capital Management Inc now owns 1,380 shares of the company's stock valued at $33,000 after purchasing an additional 1,135 shares in the last quarter. Finally, Nykredit A S purchased a new position in Alignment Healthcare during the second quarter valued at approximately $36,000. Institutional investors and hedge funds own 86.19% of the company's stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc is a technology-enabled healthcare company that provides Medicare Advantage health plans and care-management services for older adults. Through its Alignment Health Plan subsidiary, the company offers insurance coverage designed for Medicare-eligible members, including primary and specialty care coordination, prescription drug benefits, preventive services and access to a network of healthcare providers.

The company combines health-plan operations with proprietary technology intended to support personalized care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.